In fresh IPO's 77 percent fall, another warning sign for biotech investors

Ten weeks into its IPO, Menlo Therapeutics was one of the best-performing offerings, soaring more than 100 percent. On news that its drug flunked a mid-stage trial, the stock fell big.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.